All In Biotech

Drug Trial Radar · NCT03235245

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)

Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

271

Actual

Start

Oct 30, 2018

Primary completion

Oct 24, 2023

Study completion Jan 2027

Sponsor

Sponsor type
Research network
First posted
Aug 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Conditions

  • Unresectable Stage III Melanoma
  • Stage IV Melanoma

Interventions

  • Nivolumab + IpilimumabDrug

    nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.

  • Encorafenib + BinimetinibDrug

    encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: 4.1 years from first patient in

Locations

38 sites in 9 countries. Site status is shown where the registry gives one.

  • University Hospitals Copenhagen - Herlev Hospital - University Copenhagen

    Herlev, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Helsinki University Central Hospital - Dept of Oncology

    Helsinki, Finland

  • Tampere University Hospital

    Tampere, Finland

  • CHU Amiens - Hopital Sud

    Amiens, France

  • CHRU de Besançon - Hopital Jean Minjoz

    Besançon, France

  • CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre

    Bordeaux, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • CHU de Dijon - Centre Georges-François-Leclerc

    Dijon, France

  • CHU de Grenoble - La Tronche - Hôpital A. Michallon

    Grenoble, France

  • CHRU de Lille

    Lille, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Centre Leon Berard

    Lyon, France

  • Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (APHM)

    Marseille, France

  • CHU de Nice - Hopital De L'Archet

    Nice, France

  • Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis

    Paris, France

  • CHU Ambroise Pare

    Paris, France

  • Centre Hospitalier De Pau

    Pau, France

  • CHU de Saint-Etienne - Hopital Nord

    Saint-Priest-en-Jarez, France

  • CHU de Tours - Hopital Trousseau

    Tours, France

  • Gustave Roussy

    Villejuif, France

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Univ. Mainz - Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz-University Medical Center

    Mainz, Germany

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, Italy

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • IRCCS - Istituto Oncologico Veneto

    Padova, Italy

  • IRCCS-Regina Elena National Cancer Center

    Roma, Italy

  • Universita Degli Studi Di Siena -Policlinico "le Scotte"

    Siena, Italy

  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino

    Turin, Italy

  • Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine

    Udine, Italy

  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, Netherlands

  • Maria Sklodowska-Curie Memorial Cancer Centre

    Warsaw, Poland

  • Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)

    Badalona, Spain

  • Hospital Clinic Universitari de Barcelona

    Barcelona, Spain

  • Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain

  • NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital

    Glasgow, United Kingdom

  • East & North Hertfordshire NHS Trust - East and North Hertfordshire NHS Trust - Mount Vernon Hospital

    Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.